Pateras I, Igea A, Nikas I, Leventakou D, Koufopoulos N, Ieronimaki A
Int J Mol Sci. 2024; 25(2).
PMID: 38279253
PMC: 10816510.
DOI: 10.3390/ijms25021251.
Han Y, Wang J, Xu B
J Pers Med. 2023; 13(3).
PMID: 36983639
PMC: 10054905.
DOI: 10.3390/jpm13030457.
Cassetta L, Pollard J
Nat Rev Cancer. 2023; 23(4):238-257.
PMID: 36792751
DOI: 10.1038/s41568-022-00547-1.
Luque M, Sanz-Alvarez M, Morales-Gallego M, Madoz-Gurpide J, Zazo S, Dominguez C
Cancers (Basel). 2022; 14(24).
PMID: 36551522
PMC: 9776701.
DOI: 10.3390/cancers14246034.
Zhang J, Cai X, Cui W, Wei Z
Genes (Basel). 2022; 13(10).
PMID: 36292671
PMC: 9601900.
DOI: 10.3390/genes13101786.
Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer.
Tian C, Wang Y, Song X
Front Oncol. 2022; 12:878219.
PMID: 35785160
PMC: 9243266.
DOI: 10.3389/fonc.2022.878219.
Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
Uchimiak K, Badowska-Kozakiewicz A, Sobiborowicz-Sadowska A, Deptala A
Clin Med Insights Oncol. 2022; 16:11795549221099869.
PMID: 35721387
PMC: 9201309.
DOI: 10.1177/11795549221099869.
Identification of the three subtypes and the prognostic characteristics of stomach adenocarcinoma: analysis of the hypoxia-related long non-coding RNAs.
Fan Z, Wang Y, Niu R
Funct Integr Genomics. 2022; 22(5):919-936.
PMID: 35665866
DOI: 10.1007/s10142-022-00867-3.
The next wave of cellular immunotherapies in pancreatic cancer.
Yeo D, Giardina C, Saxena P, Rasko J
Mol Ther Oncolytics. 2022; 24:561-576.
PMID: 35229033
PMC: 8857655.
DOI: 10.1016/j.omto.2022.01.010.
Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients.
Feng J, Li J, Huang X, Yi J, Wu H, Zou X
Front Mol Biosci. 2021; 8:761163.
PMID: 34901155
PMC: 8662984.
DOI: 10.3389/fmolb.2021.761163.
Comparison of Tumor Infiltrating Lymphocyte Density with Histopathological Parameters and Effect on Prognosis in Head and Neck Squamous Cell Cancers.
Sari E, Tokat T, Tarhan O, Dag H, Zeki Yilmaz Y, Yener H
Sisli Etfal Hastan Tıp Bul. 2020; 54(4):438-443.
PMID: 33364884
PMC: 7751247.
DOI: 10.14744/SEMB.2019.48208.
Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer.
Pei J, Li Y, Su T, Zhang Q, He X, Tao D
Front Genet. 2020; 11:912.
PMID: 33193571
PMC: 7526716.
DOI: 10.3389/fgene.2020.00912.
Immunotherapeutic strategies in breast cancer: A clinical update.
Zhang J, Plitas G
J Surg Oncol. 2020; 123(3):710-717.
PMID: 33155281
PMC: 7889634.
DOI: 10.1002/jso.26287.
Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets.
Ren N, Liang B, Li Y
Biosci Rep. 2020; 40(10).
PMID: 33015704
PMC: 7560520.
DOI: 10.1042/BSR20200980.
Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are.
Saggioro M, DAngelo E, Bisogno G, Agostini M, Pozzobon M
Front Oncol. 2020; 10:76.
PMID: 32195166
PMC: 7063801.
DOI: 10.3389/fonc.2020.00076.
Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Wang K, Li H, Xiong Y, Shi Y, Li Z, Li J
Cancer Med. 2019; 8(2):686-700.
PMID: 30677255
PMC: 6382728.
DOI: 10.1002/cam4.1880.
Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment.
Kaimala S, Al-Sbiei A, Cabral-Marques O, Fernandez-Cabezudo M, Al-Ramadi B
Front Oncol. 2018; 8:136.
PMID: 29765907
PMC: 5938341.
DOI: 10.3389/fonc.2018.00136.
The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A
Front Oncol. 2018; 8:27.
PMID: 29515971
PMC: 5826382.
DOI: 10.3389/fonc.2018.00027.
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
Saraiva D, Cabral M, Jacinto A, Braga S
ESMO Open. 2017; 2(4):e000208.
PMID: 29018573
PMC: 5604720.
DOI: 10.1136/esmoopen-2017-000208.
The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M, Carethers J
Future Oncol. 2017; 13(18):1633-1647.
PMID: 28829193
PMC: 6817965.
DOI: 10.2217/fon-2017-0145.